Results 261 to 270 of about 221,538 (343)

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Clinical Pharmacology &Therapeutics, EarlyView.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, on behalf of the AGILE CST‐6 Study Group, Shazaad Ahmad, Christopher J. Edwards, Lesley Dry, Georgie McKenzie, Aleksandra Ros, Michael Stackpoole, Laura Bradley, Karen Jennings‐Wilding, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Steven Julious   +48 more
wiley   +1 more source

Interactive online calculator for estimation of muscle and hepatic insulin sensitivity in adults with Type 1 diabetes using clinical and research biomarkers. [PDF]

Diabetes Obes Metab
Januszewski AS, Snaith JR, Kowalski GM, Bruce CR, Holmes-Walker DJ, Jenkins AJ, Greenfield JR.   +6 more
europepmc   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Indirect estimation of serum enzymes reference intervals in adults using the reflimR and refineR algorithms. [PDF]

Biochem Med (Zagreb)
Yıldız R, Arslan FD, Köseoğlu M.
europepmc   +1 more source

Population Pharmacokinetics of Ticagrelor during Veno‐Arterial ECMO in Acute Coronary Syndrome: Model‐Informed Dosing Simulations

Clinical Pharmacology &Therapeutics, EarlyView.
Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang, Kyoung Lok Min, Seungwon Yang, Jongsung Hahn, Dasohm Kim, Byung Hak Jin, Soon Uk Chae, Soo Kyung Bae, Jin Wi, Min Jung Chang   +9 more
wiley   +1 more source

Severe Hepatitis in a Patient With Undifferentiated Connective Tissue Disease: Diagnostic Uncertainty Between Methotrexate Toxicity and Autoimmune Liver Involvement. [PDF]

Cureus
Reyad B.
europepmc   +1 more source

Diagnostic value of drug withdrawal observation in drug-induced liver injury: A retrospective study. [PDF]

Medicine (Baltimore)
Liu YH, Guo Y, Xu H, Han Y, Feng H, Pan F.   +5 more
europepmc   +1 more source

Effect of imeglimin on metabolic dysfunction-associated steatotic liver disease in individuals with type 2 diabetes. [PDF]

PLoS One
Gyoutoku N, Inoguchi Y, Rikitake J, Demiya M, Gobaru M, Nagayama A, Iwata S, Hasuzawa N, Nakayama H, Ashida K, Nomura M.   +10 more
europepmc   +1 more source

Moderate-Intensity Intermittent Walking Improves Liver-Related Biomarkers and Reduces Inflammation in Postmenopausal Women With Obesity: A Randomized Controlled Study. [PDF]

Eur J Sport Sci
Abassi W, Ouerghi N, Muscella A, Feki M, Bouassida A.   +4 more
europepmc   +1 more source